HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that NASDAQ has halted trading of Acorda common stock.
The U.S. Food and Drug Administration's ( DA) Peripheral and Central Nervous System Drugs Advisory Committee meets today to review and discuss Acorda’s New Drug Application (NDA) for Fampridine-SR for improvement of walking ability in people with multiple sclerosis (MS).
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
No comments:
Post a Comment